Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Tap
Dr. William Tap is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 17 years. Dr. Tap accepts several types of health insurance, listed below. He is one of 510 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Vanderbilt University Medical CenterResidency, Internal Medicine, 2000 - 2003
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000
Certifications & Licensure
CA State Medical License 2003 - Present
FL State Medical License 2021 - Present
NY State Medical License 2011 - 2026
NJ State Medical License 2020 - 2025
TN State Medical License 2002 - 2004
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2014
- Top Doctors: New York Metro Area Castle Connolly, 2013-2014
- America's Top Doctors for Cancer Castle Connolly, 2013
- Join now to see all
Clinical Trials
- Sorafenib and Dacarbazine in Soft Tissue Sarcoma Start of enrollment: 2009 Feb 01
- Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Start of enrollment: 2009 Apr 01
- Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Undifferentiated Pleomorphic Sarcoma in Children and Young Adults: A Comprehensive Clinicopathologic, Genomic, and Epigenetic Comparison with Adult Counterparts.Carla Saoud, Gunes Gundem, Chad M Vanderbilt, Leonard H Wexler, Damon R Reed
Modern Pathology. 2025-04-11 - Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry.Sydney Stern, Patrick F McKenzie, Nicholas Bernthal, Shannon O'Neill, Emanuela Palmerini
Future Oncology. 2025-04-08 - Methylation Analysis Reveals Epigenetic Congruence Between Bone Sarcomas With H3-3A Mutations and Malignant Giant Cell Tumors of Bone.Carla Saoud, Jamal Benhamida, Laetitia Borsu, Liliana Villafania, Konstantinos Linos
Modern Pathology. 2025-03-27
Lectures
- ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced...2019 ASCO Annual Meeting - 6/1/2019
- Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial gia...2019 ASCO Annual Meeting - 6/1/2019
- Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
FDA Approves Romvimza for Tenosynovial Giant Cell Tumor (TGCT)February 20th, 2025- FDA Grants Approval for Vimseltinib in Treatment of Tenosynovial Giant Cell Tumor (TGCT)February 19th, 2025
- Peptomyc Announces the Beginning of a Phase 2 Clinical Trial of OMO-103 in Advanced OsteosarcomaJanuary 16th, 2025
- Join now to see all
Insurance Accepted
- BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPOGreat West PPO
Health Net Oregon PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
